[go: up one dir, main page]

IL163689A0 - Novel crystalline forms of the anti-cancer compound zd1839 - Google Patents

Novel crystalline forms of the anti-cancer compound zd1839

Info

Publication number
IL163689A0
IL163689A0 IL16368903A IL16368903A IL163689A0 IL 163689 A0 IL163689 A0 IL 163689A0 IL 16368903 A IL16368903 A IL 16368903A IL 16368903 A IL16368903 A IL 16368903A IL 163689 A0 IL163689 A0 IL 163689A0
Authority
IL
Israel
Prior art keywords
solvate
trihydrate
occurs
designated
compound
Prior art date
Application number
IL16368903A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL163689A0 publication Critical patent/IL163689A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL16368903A 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839 IL163689A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
PCT/GB2003/000794 WO2003072108A1 (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839

Publications (1)

Publication Number Publication Date
IL163689A0 true IL163689A0 (en) 2005-12-18

Family

ID=27767099

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16368903A IL163689A0 (en) 2002-02-26 2003-02-24 Novel crystalline forms of the anti-cancer compound zd1839
IL163689A IL163689A (en) 2002-02-26 2004-08-23 Crystalline forms of the anti-cancer compound zd1839, processes for their preparation and pharmaceutical compositions comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL163689A IL163689A (en) 2002-02-26 2004-08-23 Crystalline forms of the anti-cancer compound zd1839, processes for their preparation and pharmaceutical compositions comprising them

Country Status (17)

Country Link
US (2) US7612077B2 (de)
EP (1) EP1480650B1 (de)
JP (1) JP4836404B2 (de)
KR (1) KR20040086452A (de)
CN (1) CN100404032C (de)
AT (1) ATE465738T1 (de)
AU (1) AU2003212500B2 (de)
BR (1) BRPI0308023B1 (de)
CA (3) CA2477350C (de)
DE (1) DE60332322D1 (de)
ES (1) ES2342660T3 (de)
HK (1) HK1070582A1 (de)
IL (2) IL163689A0 (de)
MX (1) MXPA04008330A (de)
NO (1) NO329618B1 (de)
NZ (1) NZ534871A (de)
WO (1) WO2003072108A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480679B1 (de) * 2002-02-26 2007-05-23 Astrazeneca AB Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
WO2006090413A1 (en) * 2005-02-23 2006-08-31 Natco Pharma Limited Novel crystalline form of gefitinib and a process for its preparation
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
CN101973944B (zh) * 2010-10-14 2012-07-04 江苏先声药物研究有限公司 一种Gefitinib Form 1 晶型的制备方法
AU2011319842B2 (en) 2010-10-29 2014-05-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
LT2642999T (lt) 2010-11-23 2017-01-25 Abbvie Ireland Unlimited Company Gydymo būdai, naudojant selektyviuosius bcl-2 inhibitorius
CN103319422B (zh) * 2012-03-21 2016-05-04 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼晶型及其制备方法
WO2014016848A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
CN103896862B (zh) * 2012-12-25 2017-05-10 江苏天士力帝益药业有限公司 一种吉非替尼Form 1晶型的制备方法
CN103896861A (zh) * 2012-12-26 2014-07-02 亚宝药业集团股份有限公司 抗癌化合物zd1839的无定形物及其制备方法
CN103896863B (zh) * 2012-12-26 2017-06-13 亚宝药业集团股份有限公司 抗癌化合物zd1839的晶型及其制备方法
CN103910690A (zh) * 2013-01-06 2014-07-09 上海科胜药物研发有限公司 一种吉非替尼新晶型及其制备方法
CN103102316A (zh) * 2013-01-17 2013-05-15 李彦 ZD1839Form 1晶型的制备方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN103360326B (zh) * 2013-04-19 2016-03-30 南京优科生物医药研究有限公司 吉非替尼晶型i的精制方法
US20140357723A1 (en) * 2013-05-29 2014-12-04 Uwe-Bernd Bernd Ross Tricholine Nasal Formulation and Method of Use
KR20150001936A (ko) * 2013-06-28 2015-01-07 제일약품주식회사 게피티닙의 신규한 결정형 및 이의 제조방법
WO2015170345A1 (en) 2014-05-09 2015-11-12 Council Of Scientific & Industrial Research Pharmaceutical cocrystals of gefitinib
CN107106481A (zh) * 2014-08-28 2017-08-29 通用医疗公司 可注射的浆料及其制造和使用方法
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
CN104277005A (zh) * 2014-09-19 2015-01-14 成都新恒创药业有限公司 一种吉非替尼Form 1晶型的制备方法
EP3233064A1 (de) 2014-12-19 2017-10-25 Synthon BV Pharmazeutische zusammensetzung mit gefifinib
WO2017114735A1 (en) * 2015-12-30 2017-07-06 Synthon B.V. Process for making crystalline form a of gefitinib
SG11201807138XA (en) 2016-02-26 2018-09-27 Massachusetts Gen Hospital Medical ice slurry production and delivery systems and methods
CN106083739B (zh) * 2016-05-31 2019-05-14 华南理工大学 吉非替尼新晶型及其基于超临界反溶剂技术的制备方法
CN111454221B (zh) * 2020-04-21 2023-01-06 华南理工大学 一种吉非替尼和布美他尼药物共晶体及其制备方法
CN118221595A (zh) * 2020-06-15 2024-06-21 山东新时代药业有限公司 一种吉非替尼的有机酸盐
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
EP1480679B1 (de) 2002-02-26 2007-05-23 Astrazeneca AB Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat

Also Published As

Publication number Publication date
BRPI0308023B1 (pt) 2021-07-27
JP2005525354A (ja) 2005-08-25
US7612077B2 (en) 2009-11-03
HK1070582A1 (en) 2005-06-24
ATE465738T1 (de) 2010-05-15
JP4836404B2 (ja) 2011-12-14
AU2003212500B2 (en) 2008-01-03
NO329618B1 (no) 2010-11-22
CA2702297C (en) 2014-02-04
US20050209229A1 (en) 2005-09-22
NO20044047L (no) 2004-11-16
EP1480650B1 (de) 2010-04-28
CA2833470A1 (en) 2003-09-04
AU2003212500A1 (en) 2003-09-09
US20100137304A1 (en) 2010-06-03
WO2003072108A1 (en) 2003-09-04
ES2342660T3 (es) 2010-07-12
CA2477350C (en) 2013-02-12
EP1480650A1 (de) 2004-12-01
CA2477350A1 (en) 2003-09-04
IL163689A (en) 2011-10-31
CA2833470C (en) 2016-03-29
MXPA04008330A (es) 2004-11-26
BR0308023A (pt) 2004-12-28
CN1652790A (zh) 2005-08-10
CA2702297A1 (en) 2003-09-04
NZ534871A (en) 2007-05-31
DE60332322D1 (de) 2010-06-10
CN100404032C (zh) 2008-07-23
KR20040086452A (ko) 2004-10-08

Similar Documents

Publication Publication Date Title
HK1070582A1 (en) Novel crystalline forms of the anti-cancer compound zd1839
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
HUP0401982A2 (hu) Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
JO2707B1 (ar) مشتقات ثيوفين جليكوسايد جديدة, طرق تحضيرها, والادوية المحتوية على هذه المركبات واستخدامها
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
SE0400284D0 (sv) Novel compounds
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
NZ547565A (en) Substituted arylpyrazoles as parasiticidal agents
CR8842A (es) Derivados de pirido-pirimidina, su preparacion, su aplicacion en terapeutica
TW200612920A (en) Novel imidazolidine derivatives
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
UY29169A1 (es) Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
JO2689B1 (en) New vehicles
PL376896A1 (pl) Sposoby wytwarzania 5-androstenów podstawionych w pozycji C-7
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
RS56004A (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
DE60114640D1 (en) Antithrombosemittel
TW200510366A (en) 1, 2, 4-trioxepanes as precursors for lactones
BG107050A (en) Method for the preparation of citalopram
YU76500A (sh) Hemijska sinzeza morfolinskih derivata
GB0327323D0 (en) Novel pharmaceuticals

Legal Events

Date Code Title Description
FF Patent granted